DV3R Stock Overview
An interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Delcath Systems, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.20 |
| 52 Week High | US$7.85 |
| 52 Week Low | US$2.16 |
| Beta | 0.60 |
| 11 Month Change | 18.03% |
| 3 Month Change | 56.52% |
| 1 Year Change | 38.46% |
| 33 Year Change | -24.21% |
| 5 Year Change | n/a |
| Change since IPO | -52.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| DV3R | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -5.9% | -3.5% | 0.8% |
| 1Y | 38.5% | 2.2% | 6.1% |
Return vs Industry: DV3R exceeded the German Medical Equipment industry which returned 2.2% over the past year.
Return vs Market: DV3R exceeded the German Market which returned 6.1% over the past year.
Price Volatility
| DV3R volatility | |
|---|---|
| DV3R Average Weekly Movement | 10.6% |
| Medical Equipment Industry Average Movement | 4.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: DV3R's share price has been volatile over the past 3 months.
Volatility Over Time: DV3R's weekly volatility has decreased from 17% to 11% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 76 | Gerard Michel | www.delcath.com |
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma.
Delcath Systems, Inc. Fundamentals Summary
| DV3R fundamental statistics | |
|---|---|
| Market cap | €203.26m |
| Earnings (TTM) | -€46.04m |
| Revenue (TTM) | €4.26m |
47.7x
P/S Ratio-4.4x
P/E RatioIs DV3R overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DV3R income statement (TTM) | |
|---|---|
| Revenue | US$4.61m |
| Cost of Revenue | US$1.36m |
| Gross Profit | US$3.25m |
| Other Expenses | US$53.04m |
| Earnings | -US$49.79m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.79 |
| Gross Margin | 70.54% |
| Net Profit Margin | -1,080.73% |
| Debt/Equity Ratio | 50.3% |
How did DV3R perform over the long term?
See historical performance and comparison